[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-arrhythmia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-arrhythmia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,42,69,103,132,155,177,213,234,260,281,308,332,359,385,411,436,456,487,511,534,563],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642550","association-between-circulating-bdnf-levels-and-atrial-cardiomyopathy-in-patients-undergoing-ablation-for-persistent-atrial-fibrillation-100642550",false,"NCT07648329","Association Between Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation","METAPROFIL 2","Inclusion Criteria:\n\n* Participants who have provided written consent\n* Patients aged 18 years or older.\n* Patients scheduled to undergo their first ablation procedure for persistent atrial fibrillation at the Dijon Bourgogne University Hospital\n\nExclusion Criteria:\n\n* A person who is not enrolled in or eligible for a social security program\n* A person subject to a legal protective measure (guardianship, conservatorship)\n* Person subject to a judicial safeguard measure\n* Pregnant or breastfeeding woman\n* Adult who is legally incapacitated or unable to give consent\n* Ablation of paroxysmal AF with or without electroanatomical mapping","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","trial fibrillation (AF) is the most common cardiac arrhythmia worldwide, and its prevalence continues to rise. AF is associated with serious complications, including embolic strokes, heart failure, and mortality. Characterized by rapid, irregular, and weakened contractions of the atria, AF is considered one of the \"visible\" electrophysiological manifestations of a broader condition known as atrial cardiomyopathy (ACM). Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, predisposes to thrombus formation. Once dislodged from the atrial cavity and migrating to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for ACI\u002FAF are metabolic syndrome and aging. CMA is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, we aim to address this challenge by approaching CMA through one of its complications: persistent atrial fibrillation. Indeed, CMA can be assessed using electroanatomical mapping during atrial fibrillation ablation (AFA) procedures. During radiofrequency ablation of AF, electroanatomical mapping of the left atrium is performed to measure left atrial voltage, which serves as an indirect marker of the presence of atrial fibrosis, strongly associated with CMA. Other parameters relevant to the identification of CMA can be assessed during this procedure, such as conduction velocities and specific electrographic characteristics.\n\nWe plan to include 150 patients undergoing ablation for persistent atrial fibrillation at the Dijon Bourgogne University Hospital and to correlate circulating levels of BDNF (brain-derived neurotrophic factor) with electroanatomical mapping data of the left atrium. The electrical remodeling of the left atrium, including low-voltage areas and conduction velocity, as well as left atrial morphology assessed by pre-procedural cardiac computed tomography using the ADAS3 Galgo LA Module software, will be correlated with BDNF levels. Blood samples for BDNF assessment will be collected before or at the start of the ablation procedure, prior to any catheter insertion into the vessels.\n\nWhile investigating the association between BDNF levels and CMA characteristics during AF ablation, thereby confirming the pathophysiological relationship with atrial remodeling, our objective is also to evaluate the prognostic role of BDNF levels in clinical and rhythm outcomes following AF ablation. Thus, we will compare changes in BDNF levels after AF ablation at one-year follow-up, correlating them with the evolution of CMA-based on left atrial parameters assessed by echocardiography or cardiac computed tomography-autonomic nervous system balance and heart rhythm obtained via Holter monitoring, as well as clinical outcomes.",[24,25,26,27,28],"Atrial Fibrillation (AF)","Cardiac Arrhythmia","Atrial Fibrillation Ablation","BDNF","Atrial Cardiomyopathy","NOT_YET_RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":35,"type":20},"2026-07",{"date":37,"type":20},"2029-07",{"name":39,"class":40},"Centre Hospitalier Universitaire Dijon","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100528748","cardiac-arrhythmia-telemetry-conventional-vs-heartwatch-100528748","NCT06164808","Cardiac Arrhythmia Telemetry; Conventional vs HeartWatch","CATCH","Inclusion Criteria:\n\n* At least 22 years of age at time of consent\n* Clinically indicated for a Holter monitor test\n* Able to wear the HeartWatch on the left bicep for the study duration\n* Able to follow the protocol\n* No functional implantable pacemaker or defibrillator\n* Left bicep circumference \\>\u002F= 22 cm and \\\u003C\u002F= 45 cm\n* Provision of written-informed consent\n\nExclusion Criteria:\n\n* Known allergy to any component of the Holter monitor\n* Known allergy to any component of the HeartWatch\n* Inability to wear the HeartWatch on the left arm for the study period due to pre-existing medical condition (3.g., functional AV fistula in left arm, prior carcinoma with lymph node dissection or lymphedema, known blood clot of recurrent blood clots in the left arm, chronic neuropathic pain in left arm, ...)\n* Dextrocardia\n* Implanted functional Pacemaker or Defibrillator\n* Left bicep circumference \\\u003C 22 cm\n* Left bicep circumference \\\u003C 45 cm","22 Years",{"count":51,"type":20},300,"INTERVENTIONAL",[54],"NA","Heart rhythm disorders are common and significantly impact the lives of those affected and their families. The main problems can be categorized as: a) atrial fibrillation or AF and atrial flutter, b) supra-ventricular tachycardia or SVT, c) excessively slow heart beats (i.e., bradycardia or pauses) and d) ventricular arrhythmias. These problems can be difficult to detect with currently available monitoring options as they are all worn for shorter terms or are an invasive implantable option. The HeartWatch is a longer term monitoring system that is worn on the upper arm, allows users to create a tag and pairs with an app on a smartphone allowing for correlation of symptoms.",[25,57,24],"Diagnostic\u002FMonitoring Devices Related to Adverse Incidents","RECRUITING","2026-06-05",{"date":61,"type":33},"2026-06-09",{"date":63,"type":33},"2024-02-20",{"date":65,"type":20},"2026-12-31",{"name":67,"class":68},"HelpWear Inc.","INDUSTRY",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":52,"phases":79,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":41},"100640379","in-hospital-wearable-based-monitoring-versus-standard-care-in-cardiovascular-disease-inspire-100640379","NCT07622485","In-Hospital Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease (INSPIRE)","In-Hospital Efficacy and Safety of Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease: A Stepped-Wedge Cluster Randomized Controlled Trial (INSPIRE Trial)","Inclusion Criteria:\n\nAdults aged 20 years or older\n\n* Hospitalized for cardiovascular disease, with at least one of: acute coronary syndrome; chronic coronary syndrome; acute heart failure (NYHA class III-IV or acute decompensated heart failure); arrhythmia (atrial fibrillation, ventricular tachycardia, complete AV block, or other clinically significant arrhythmia); peripheral arterial or aortic disease; post-cardiovascular-procedure observation (PCI, CABG, valve surgery, or electrophysiology study); or thromboembolic disease\n* Able to provide written informed consent\n* Able to wear the wearable monitoring device\n\nExclusion Criteria:\n\n* Hemodynamically unstable shock (sustained systolic blood pressure \\\u003C 90 mmHg requiring vasopressors; cardiogenic shock; septic shock)\n* Planned or current intensive care unit admission\n* Within 24 hours after cardiopulmonary resuscitation\n* Physical condition precluding device wearing (bilateral upper-limb amputation; severe skin lesion, burn, or open wound at the device site; known allergy to device materials)\n* Severe cognitive impairment or delirium precluding informed consent Extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP) in use\n* Continuous renal replacement therapy (CRRT) in use (patients on CRRT may participate if hemodynamically stable and device wearing is technically feasible)\n* Unable to communicate in Korean for study explanation and the consent process\n* Previously enrolled in this study (re-admitted patients are not re-enrolled; each participant is enrolled only at the first admission)\n* Considered inappropriate for participation by the investigator","20 Years",{"count":78,"type":20},1500,[54],"Patients hospitalized with cardiovascular disease require timely detection of clinical deterioration to prevent adverse outcomes. Standard inpatient care relies on intermittent nursing vital-sign measurements performed every 4 to 8 hours, which can miss hemodynamic or arrhythmic events occurring between measurements. This trial evaluates whether digital wearable-based monitoring - wireless continuous measurement of vital signs and electrocardiography with a real-time alerting system - reduces major adverse cardiovascular events (MACE) compared with standard intermittent monitoring in patients hospitalized for cardiovascular disease. The trial uses a stepped-wedge cluster-randomized design in which four inpatient ward zones (clusters) are sequentially transitioned from standard care to wearable monitoring over five periods.",[82,83,84,25,85],"Cardiovascular Diseases","Acute Coronary Syndrome","Heart Failure","Peripheral Arterial Disease",[87,88,89,90,91,92,93],"wearable device","continuous monitoring","remote monitoring","stepped-wedge cluster trial","major adverse cardiovascular events","digital health","inpatient monitoring","2026-06-01",{"date":96,"type":33},"2026-06-03",{"date":98,"type":20},"2026-07-01",{"date":100,"type":20},"2029-12-31",{"name":102,"class":40},"Yonsei University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":52,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":41},"100594373","ns-pfa-catheter-ablation-of-paroxysmal-atrial-fibrillation-with-the-pulse-biosciences-cellfx-system-100594373","NCT07018596","NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System","Safety and Effectiveness of the CellFX® nsPFA Catheter Endocardial Ablation System for the Treatment of Paroxysmal Atrial Fibrillation","NANOPULSE-AF","Inclusion Criteria:\n\n* A diagnosis of recurrent drug-resistant symptomatic paroxysmal AF defined as AF that terminates spontaneously or with intervention within seven (7) days of onset, documented by the following:\n\n  i. Physician's note indicating the presence of AF symptoms and at least two (2) episodes of self-terminating AF within six (6) months prior to enrollment\n* Age 18 through 85 years old (or older than 18 if required by local law)\n* Failure of at least one AAD (class I or III) for AF as evidenced by recurrence of symptomatic AF, or intolerable side effects due to AAD.\n* Participant is willing and capable of providing Informed Consent\n* Received a standard cardiac work up and is an appropriate candidate for an investigational procedure as determined by study investigators\n\nExclusion Criteria:\n\n* Left atrial diameter ≥5.5 cm (anteroposterior)\n* Any of the following within 3 months prior to enrollment:\n\n  1. Any cardiac surgery\n  2. Myocardial infarction\n  3. Percutaneous Coronary Intervention (PCI) \u002F Percutaneous Coronary Intervention (PTCA) or coronary artery stenting\n  4. Unstable angina\n  5. Pericarditis or symptomatic pericardial effusion\n* Any of the following within 6 months prior to enrollment:\n\n  1. Any cerebral ischemic event (stroke or transient ischemic attack (TIA)\n  2. History of thromboembolic event\n* Prior history of medical procedure involving instrumentation of the left atrium (previous ablation, atrial septal defect (ASD) closure, Left atrial appendage occlusion)\n* Planned Left Atrial Appendage (LAA) closure procedure, Transcatheter Aortic Valve Replacement (TAVR), Mitraclip, Atrial Septal Defect (ASD) or Patent Foramen Ovale (PFO) closure, Triclip or implant of an Implantable Loop Recorder (ILR), permanent pacemaker, biventricular pacemaker, or any implantable cardiac defibrillator (with or without biventricular pacing function) during or for any time during the follow-up period\n* Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure\n* Documented left atrial (LA) thrombus by imaging within 48 hours of the procedure.\n* Presence of a permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator (with or without biventricular pacing function).\n* Prior diagnosis of pulmonary vein stenosis\n* Valvular cardiac surgical\u002Fpercutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).\n* Moderate to severe mitral valve stenosis\n* More than moderate mitral regurgitation (i.e., 3+ or 4+ MR)\n* New York Heart Association (NYHA) Class III or IV congestive heart failure or documented left ventricular ejection fraction (LVEF) less than or equal to 35% measured by acceptable cardiac testing (e.g., TTE)\n* History of pulmonary hypertension with pulmonary systolic artery pressure \\>50 mm Hg, severe Chronic Obstructive Pulmonary Disease or restrictive lung disease\n* Rheumatic heart disease\n* Contraindication to anticoagulation (i.e., Heparin, Dabigatran, Apixaban, Vitamin K Antagonists such as warfarin)\n* Active systemic infection\n* Hypertrophic or advanced infiltrative cardiomyopathy\n* Atrial myxoma\n* Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism, severe untreated obstructive sleep apnea, and acute alcohol toxicity\n* History of abnormal bleeding and\u002For clotting disorder\n* Renal insufficiency with an estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2, or any history of renal dialysis or renal transplant\n* History of severe chronic gastrointestinal problems involving the esophagus, stomach and\u002For untreated acid reflux\n* Solid organ or hematologic transplant, or currently being evaluated for an organ transplant\n* Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence\n* Other criteria, which the Investigator determines would make the patient unsuitable to participate (e.g. uncontrolled drug and\u002For alcohol addiction, congenital disease, fragility)\n* Body Mass Index (BMI) \\> 40.0\n* Participants with any other significant uncontrolled or unstable medical condition (such as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or significant coagulation disorder)\n* Life expectancy less than one year\n* Current or anticipated participation in any other clinical study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor\n* Unwilling or unable to comply fully with study procedures and follow-up","85 Years",{"count":113,"type":20},215,[54],"The objective of this study is to demonstrate the safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA) Cardiac Catheter Ablation System in treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF).",[117,118,25],"Atrial Fibrillation Paroxysmal","Cardiac Ablation",[120,121,122],"nsPFA","Pulsed Field Ablation","nano-PFA","2026-05-03",{"date":125,"type":33},"2026-05-06",{"date":127,"type":33},"2026-04-06",{"date":129,"type":20},"2028-01",{"name":131,"class":68},"Pulse Biosciences, Inc.",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":52,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100569586","cellfx-nanosecond-pulsed-field-ablation-pfa-360-catheter-ablation-system-for-treatment-of-atrial-fibrillation-100569586","NCT06696170","CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation","Initial Safety and Performance of the CellFX® Nano-PFA 360 Catheter Endocardial Ablation System for the Treatment of Atrial Fibrillation","Inclusion Criteria:\n\n* Subject must be ≥ 18 and ≤ 75 years of age on the day of enrollment\n* Subject is willing and capable of providing Informed Consent to undergo study procedures and participate in all examinations and follow-up visits and tests associated with this clinical study\n* Subjects with PAF who have had at least one AF episode documented within one (1) year prior to enrollment. Documentation may include ECG, transtelephonic monitor (TTM), Holter monitor (HM), or telemetry strip\n* Subjects who have failed at least one antiarrhythmic drug (AAD; class I or III, or AV nodal blocking agents such as beta blockers and calcium channel blockers) as shown by recurrent symptomatic AF, or intolerance to the AAD or AV nodal blocking agents\n* Antero-posterior left atrial diameter ≤ 5.5 cm as documented by transthoracic echocardiography (TTE) or computed tomography (CT) within 3 months prior to the procedure\n* Left ventricular ejection fraction ≥ 40% as documented by TTE within 12 months prior to the procedure\n* Received a standard cardiac work up and is an appropriate candidate for an investigational procedure as determined by the study investigators\n\nExclusion Criteria:\n\n* Subject has an implantable electronic medical device. (i.e., pacemaker, ICD or CRT) or left atrial appendage device\n* Subject has a prosthetic heart valve\n* AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause\n* AF episodes lasting \\> 7 days\n* Previous ablation for AF\n* Subjects on amiodarone at any time during the past 3 months prior to enrollment\n* Prior history of pericarditis or pericarditis within 3 months based on the TTE examination\n* Prior history of rheumatic fever\n* Prior history of medical procedure involving instrumentation of the left atrium (previous ablation, atrial septal defect (ASD) closure, left atrial appendage occlusion)\n* History of severe chronic gastrointestinal problems involving the esophagus, stomach and\u002For untreated acid reflux\n* History of abnormal bleeding and\u002For clotting disorder\n* Contraindication to anticoagulation (i.e., Heparin, Dabigatran, Apixaban, Vitamin K Antagonists such as Warfarin)\n* Active malignancy or history of treated cancer within 24 months of enrollment\n* Clinically significant infection or sepsis on the day of index procedure with either fever, leukocytosis or requiring intravenous antibiotics\n* History of stroke or TIA within prior 6 months, or any prior intracranial hemorrhage or permanent neurological deficit\n* New York Heart Association (NYHA) class IIIb or IV congestive heart failure and\u002For any heart failure hospitalization within 3 months prior to enrollment\n* Body mass index \\> 35 kg\u002Fm2\n* Estimate glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m2 or has ever received hemodialysis\n* History of untreated and serious hypotension, bradycardia or chronotropic incompetence\n* Any of the following within 3 months of enrollment:\n\n  1. Major surgery except for the index procedure\n  2. Myocardial infarction\n  3. Unstable angina\n  4. Percutaneous coronary intervention\n  5. Sudden cardiac death event\n  6. Left atrial thrombus that has not resolved as shown by TEE or CT\n* Solid organ or hematologic transplant, or currently being evaluated for an organ transplant\n* History of pulmonary hypertension with pulmonary systolic artery pressure \\>50 mm Hg, severe Chronic Obstructive Pulmonary Disease or restrictive lung disease\n* Subjects with any other significant uncontrolled or unstable medical condition (such as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or significant coagulation disorder)\n* Life expectancy less than one year\n* Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.\n* Females of childbearing potential who are nursing, pregnant, or planning to become pregnant during the study period\n* Other criteria, which the Investigator determines would make the patient unsuitable to participate (e.g. uncontrolled drug and\u002For alcohol addiction, congenital disease, fragility)","75 Years",{"count":141,"type":20},60,[54],"The objective of this study is to demonstrate initial safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA or nano-PFA) 360 Catheter Endocardial Ablation System in treating subjects with atrial fibrillation.",[117,118,25],[120,146,121,122],"CellFX",{"date":148,"type":33},"2026-05-05",{"date":150,"type":33},"2024-07-25",{"date":152,"type":20},"2026-07-25",{"name":131,"class":68},3,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":162,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100636922","the-effects-of-low-flow-and-normal-flow-sevoflurane-anesthesia-on-frontal-qrs-t-angle-and-tp-e-interval-100636922","NCT07571980","The Effects of Low-Flow and Normal-Flow Sevoflurane Anesthesia on Frontal QRS-T Angle and TP-e Interval","The Effects of Low-Flow and Normal-Flow Sevoflurane Anesthesia on Frontal QRS-T Angle and TP-e Interval in Patients Undergoing Elective Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients scheduled for elective or semi-elective laparoscopic cholecystectomy.\n* Patients who provide written voluntary informed consent.\n* Patients with a predicted surgical duration between 60 and 180 minutes.\n\nExclusion Criteria:\n\n* Patients with heart failure.\n* Patients with valvular heart disease or pathology.\n* Patients with hemodynamic instability.\n* Patients requiring blood transfusion.\n* Patients with a preoperative corrected QT (QTc) interval \\> 450 ms.\n* Patients with a known history of cardiac arrhythmia.\n* Patients scheduled for emergency surgery.\n* Patients with a known risk or family history of malignant hyperthermia.\n* Use of medications associated with QT interval prolongation (e.g., ketamine, 5-HT3 antagonists, quetiapine, etc.).",true,{"count":164,"type":20},128,"Laparoscopic cholecystectomy procedures involve pneumoperitoneum and volatile anesthetics, both of which can significantly influence cardiovascular physiology and autonomic balance. While volatile anesthetics are known to affect myocardial repolarization, the specific impact of Low-Flow Anesthesia (LFA)-a cost-effective and environmentally friendly technique-on these cardiac markers remains under-researched.\n\nThis prospective observational study aims to compare the effects of low-flow versus normal-flow sevoflurane anesthesia on two critical non-invasive biomarkers of ventricular repolarization: the Frontal QRS-T angle and the Tp-e interval. These parameters are essential for predicting electrical instability and the risk of malignant arrhythmias. The study will evaluate a total of 128 patients to determine whether different fresh gas flow rates lead to significant changes in cardiac electrophysiological stability during the perioperative and early postoperative periods.",[25,167],"Anesthesia","2026-04-30",{"date":170,"type":33},"2026-05-07",{"date":172,"type":20},"2026-05-15",{"date":174,"type":20},"2027-08-15",{"name":176,"class":40},"Istanbul University",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":162,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",{"count":185,"type":20},1000,"Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[188,189,190,82,191,192,193,194,195,196,197,25,198,199,200,201,202],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Heart Diseases","Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Sarcoidosis","Cardiac Sarcoidosis","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":205,"type":33},"2026-04-27",{"date":207,"type":33},"2018-02-09",{"date":209,"type":20},"2027-03",{"name":211,"class":40},"Mayo Clinic",2,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":52,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":41},"100427259","stereotactic-ablative-radiotherapy-of-cardiac-arrhythmias-100427259","NCT04843683","StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias","StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias (START-CA): a Phase II Trial of Non-Invasive Treatment of Medically Refractory Patients","START-CA","Inclusion Criteria:\n\n* Patients with heart rate and rhythm condition (arrhythmia) who have failed standard of care treatment with medication OR at least one prior invasive catheter ablation procedure.\n* Patients deemed medically fit to receive stereotactic ablative radiotherapy as determined by their Radiation Oncologist.\n\nExclusion Criteria:\n\n* Patients who have previously received high dose radiotherapy to the target area and cannot safely receive further treatment OR are unable to receive radiotherapy due to other contraindications.",{"count":141,"type":20},[54],"This is a prospective, single-center, phase II trial that will be monitoring the safety and efficacy of using stereotactic ablative radiotherapy (SBRT) to treat patients with a medical condition affecting heart rate and rhythm (refractory arrhythmias) within the University Health Network (Princess Margaret Cancer Centre and Toronto General Hospital). The primary objective will be to prospectively monitor patient cardiac outcomes following SBRT.",[25],"2026-03-03",{"date":227,"type":33},"2026-03-05",{"date":229,"type":33},"2021-12-14",{"date":231,"type":20},"2027-12",{"name":233,"class":40},"University Health Network, Toronto",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":52,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":41},"100521616","emergency-resuscitative-endovascular-balloon-occlusion-of-the-aorta-in-out-of-hospital-cardiac-arrest-100521616","NCT06071910","Emergency Resuscitative Endovascular Balloon Occlusion of the Aorta in Out of Hospital Cardiac Arrest","ERICA-ARREST","Inclusion criteria\n\n* Non-Traumatic OHCA in patients within the East of England area AND with a East Anglian Air Ambulance (EAAA) REBOA team in attendance\n* Patients below or equal to 80yrs of age and above or equal to 18yrs of age, according to available information\u002Festimate at scene\n* No flow \\\u003C10 mins from data available (i.e. total period in OHCA with no CPR)\n* In cardiac arrest (with no sustained ROSC) on arrival of the EAAA REBOA team\n\nExclusion criteria\n\n* Patients aged less than 18 or above 80 years\n* Known terminal illness\n* Multiple severe co-morbidities\n* Traumatic Cardiac Arrest (TCA)\n* Inability to deploy mechanical CPR (e.g. LUCAS Device)\n* Pregnancy, obvious or suspected","80 Years",{"count":243,"type":20},40,[54],"This study will assess the feasibility of performing pre-hospital resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct to conventional Advanced Life Support (ALS) in patients suffering from non-traumatic out of hospital cardiac arrest (OHCA). As well as providing valuable insights into the technical feasibility of performing this procedure as part of a resuscitation attempt, the study will also document the beneficial physiological effects of REBOA in this group of patients.",[247,248,25,249,250,251],"Out-Of-Hospital Cardiac Arrest","Cardiac Arrest","Ventricular Fibrillation","Ventricular Arrythmia","Pulseless Electrical Activity","2026-02-26",{"date":254,"type":33},"2026-03-02",{"date":256,"type":33},"2024-06-04",{"date":65,"type":20},{"name":259,"class":40},"Queen Mary University of London",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":267,"targetDuration":269,"studyType":21,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":41},"100482355","post-market-clinical-follow-up-data-collection-from-procedures-with-biotronik-ep-products-100482355","NCT05560958","Post-market Clinical Follow-up Data Collection From Procedures With BIOTRONIK EP Products","BIO|COLLECT-EP","Inclusion Criteria:\n\n* Indication for diagnostic or therapeutic EP intervention\n* EP intervention is planned to involve the use of BIOTRONIK EP products from at least 2 of the 3 following categories:\n\n  * BIOTRONIK catheter (AlCath, ViaCath, MultiCath, Khelix)\n  * BIOTRONIK external device (Qubic Stim, Qubic RF, Qiona)\n  * BIOTRONIK transseptal sheath (Senovo Bi-Flex)\n* BIOTRONIK EP product is planned to be used within its intended purpose\n* Ability to understand the nature of the study\n* Willingness to provide written informed consent\n* Ability and willingness to perform all follow-up visits at the study site\n\nExclusion Criteria:\n\n* Age less than 18 years\n* Pregnant or breastfeeding\n* Prior participation in this study with performed EP procedure\n* Participation in an interventional clinical investigation in parallel to the BIO\\|COLLECT.EP study",{"count":268,"type":20},280,"6 Months","This data collection is designed to provide evidence for the safety, performance, and clinical benefit of BIOTRONIK's EP products. Additionally, residual risks will be monitored and newly emerging risks identified.",[25],"2025-09-16",{"date":274,"type":33},"2025-09-17",{"date":276,"type":33},"2023-01-16",{"date":278,"type":20},"2030-07",{"name":280,"class":68},"Biotronik SE & Co. KG",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":288,"targetDuration":290,"studyType":21,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":41},"100607196","spanish-registry-of-redo-procedures-following-pulmonary-vein-ablation-by-pulsed-field-ablation-technology-reset-pfa-100607196","NCT07185412","Spanish Registry of Redo Procedures Following Pulmonary Vein Ablation by Pulsed Field Ablation Technology: RESET-PFA","RESET-PFA","Inclusion Criteria:\n\n* Patients with an indication to a pulsed-field ablation procedure of Atrial Fibrillation according to current international and local guidelines (and future revisions), existing IFU or per physician discretion\n* Patients who are willing and capable of providing informed consent, participating in all testing at an approved clinical investigational center or such consent will be provided by a legal representative, if required by local law or regulation.\n\nExclusion Criteria:\n\n* Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments\n* Patients who are unwilling or unable to sign an authorization to use and disclose health information or an Informed Consent.\n* Patients unavailable or not willing to complete follow up visits and examination for the duration of the study at the center.\n* Life expectancy ≤ 12 months per physician judgment.",{"count":289,"type":20},1100,"1 Year","RESET-PFA is a prospective, multicenter, non-randomized post-market study. All patients will be treated according to the standard care followed by each center. The protocol requires enrollment of consecutive patients from each center, according to eligibility criteria. During the 12 months follow-up period, clinical atrial fibrillation recurrence, occurrence of all kinds of atrial arrhythmias and of all Adverse Events in the study population will be collected.\n\nThe purpose of this study is to prospectively evaluate during time a large population of patients with an indication for ablation of AF, collecting data on procedural success in the acute and medium- to long-term follow-up. The primary objective of the study is the determination of up to 10 clinical and procedural parameters predicting a repeat ablation procedure after the blanking period in patients that had undergone an AF ablation with pulsed field ablation through a standard of care pathway.",[25,293,121],"Atrial Fibrillation",[121,295,296,297,298],"Atrial fibrillation","Pulmonary vein isolation","Redo procedure","Mapping system","2025-09-15",{"date":301,"type":33},"2025-09-22",{"date":303,"type":20},"2025-10-01",{"date":305,"type":20},"2030-12-31",{"name":307,"class":40},"Instituto de Investigación Sanitaria Aragón",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":316,"targetDuration":4,"studyType":52,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":41},"100523481","investigation-of-cardioversion-versus-therapeutic-ablation-for-persistent-af-orbica-af-100523481","NCT06096246","Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)","Objective Randomised Blinded Investigation of Cardioversion Versus Ablation for Persistent Atrial Fibrillation (ORBICA-AF)","ORBICA-AF","Inclusion Criteria:\n\n* Ability to give informed consent\n* Age 18-85 years\n* Persistent AF (atrial fibrillation lasting \\> 7days) of total continuous duration \\\u003C2 years as documented in medical notes.\n* Patients being considered for cardioversion.\n\nExclusion Criteria:\n\n* Creatinine clearance (eGFR) \\\u003C 30mls\u002Fmin\n* Contraindication or unable to take anticoagulation\n* Uncontrolled hypertension\n* Contraindication for catheter ablation\n* BMI \\> 40\n* Patients in Persistent AF who have had more than one previous cardioversion.\n* Established diagnosis of Hypertrophic cardiomyopathy",{"count":317,"type":20},208,[54],"The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.",[321,25,322],"Persistent Atrial Fibrillation","Catheter Ablation","2025-09-01",{"date":325,"type":33},"2025-09-03",{"date":327,"type":33},"2024-07-26",{"date":329,"type":20},"2027-12-05",{"name":331,"class":40},"Barts & The London NHS Trust",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":269,"studyType":21,"phases":4,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":4},"100385175","quality-of-cardiopulmonary-resuscitation-pre--and-intra-hospital-100385175","NCT04295291","Quality of Cardiopulmonary Resuscitation Pre- and Intra Hospital","Inclusion Criteria:\n\n* cardiac arrest (all reasons)\n* a defibrillator has been used\n* over 18 years\n* cardiopulmonary resuscitation has been conducted\n\nExclusion Criteria: N\u002FA",{"count":51,"type":20},"The survival after intrahospital cardiac arrest has been reported to 15%. In Norway this varies between 16 and 23%.). Many factors are associated with survival after cardiac arrest, both intra- and prehospital. Recent studies have not included information about individual patient factors and the outcome after cardiopulmonary resuscitation (CPR). In the current hospital, we are able to record patient specific information related to a cardiac arrest\u002FCPR situation, and thereby be able to assess patient-related factors associated with both detection, treatment and outcome of CPR.",[341,248,25,342],"Cardiac Death","Cardiac Disease",[344,345,346,347,348,349],"Cardiopulmonary resuscitation","Defibrillation","Ventilation","Quality","Mortality","Morbidity","2025-08-03",{"date":352,"type":33},"2025-08-05",{"date":354,"type":20},"2026-01-01",{"date":356,"type":20},"2028-12-31",{"name":358,"class":40},"Ostfold University College",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":52,"phases":369,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":382,"locationsCount":384},"100507690","phase-3-colchicine-after-electrocardioversion-for-atrial-fibrillation-100507690","NCT05890664","Colchicine After Electrocardioversion for Atrial Fibrillation","Colchicine After Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial","COLECTRO-AF","Inclusion Criteria:\n\n* Age \\>18 years\n* ECG-documented AF prior to ECV\n* Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV\n* Ability to give written informed consent\n\nExclusion Criteria:\n\n* AF persistence after cardioversion or early AF recurrence within 30 minutes after ECV\n* Any other rhythm than AF before cardioversion\n* Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV\n* Known intolerance or hypersensitivity to Colchicine\n* Any other absolute indication for Colchicine intake\n* Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole)\n* Serious gastrointestinal disease (severe gastritis or diarrhea)\n* Clinically overt hepatic disease\n* Severe renal disease (eGFR\\< 30ml\u002Fmin\u002F1.73m2)\n* Clinically significant blood dyscrasia (e.g., myelodysplasia)\n* Significant immunosuppression (e.g. due to transplantation or rheumatic disease)\n* Pregnant or breastfeeding women, or women of child-bearing potential who do not use a highly effective form of birth control\n* Life expectancy \\<1 year",{"count":368,"type":20},416,[370],"PHASE3","The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.",[293,25],[374,375],"Electrocardioversion","Colchicine","2025-05-21",{"date":378,"type":33},"2025-05-28",{"date":380,"type":33},"2024-04-14",{"date":209,"type":20},{"name":383,"class":40},"University Hospital, Basel, Switzerland",8,{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":52,"phases":393,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":41},"100582965","smart-textile-ecg-monitoring-100582965","NCT06870175","Smart Textile ECG Monitoring","Non-Invasive Ambulatory Monitoring of Electrocardiogram (ECG) and Arrhythmia Detection Using Textile Electrodes","Inclusion Criteria:\n\n* Being referred to the Partners in Advanced Cardiac Evaluation (PACE Cardiology), and having been prescribed a 14-day ambulatory ECG monitoring by their physician.\n* Able to understand and speak English language, enough to provide informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* Cardiovascular Implantable Electronic Devices (CIED), including Implanted cardioverter defibrillator (ICD) or pacemakers\n* Absence of chest band that fits the participant's body\n* Open wound or dressing on a body part that needs to be in contact with the Skiin garment",{"count":51,"type":20},[54],"This research is a clinical evaluation of the Skiin chest band, a smart garment with embedded electronic textile (e-textile) electrodes, to record body surface electrocardiogram (ECG) signals. Developed by Myant Textile Computing Inc., the Skiin chest band (i.e. as part of the Skiin Underwear family of garments) is a component of the Myant Health Platform (MHP). The MHP also consists of: (a) a mobile phone application (Skiin Connected Life Application; SCLA), and (b) the Myant Virtual Clinic Portal (MVCP). In this study, participants will wear the Skiin chest band to collect their ECG for a period of 14 days. Participants will also be provided with a smartphone that is pre-loaded with the SCLA to record any symptoms (e.g. palpitations, shortness of breath, fatigue, light- headedness, fainting, etc.) they may experience over the 14 day ECG monitoring period. The data collected in this study will be used to develop new algorithms and patient monitoring tools to detect and predict cardiovascular health problems.",[25],[397,398,399,400,401],"Smart Textile","Ambulatory Electrocardiogram Monitoring","Holter Monitoring","Arrhythmia detection","Textile electrodes","2025-04-14",{"date":404,"type":33},"2025-04-17",{"date":406,"type":33},"2025-02-19",{"date":408,"type":20},"2026-02-19",{"name":410,"class":68},"Myant Medical Corp.",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":418,"targetDuration":269,"studyType":21,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":41},"100396116","accuracy-of-cardiac-arrhythmias-and-conduction-disorders-diagnosis-using-a-smartwatch-100396116","NCT04437914","Accuracy of Cardiac Arrhythmias and Conduction Disorders Diagnosis Using a Smartwatch","Accuracy of Cardiac Arrhythmias and Conduction Disorders Diagnosis Using Smartwatch in Comparison to Conventional Electrocardiogram in Patients With Cardiovascular Disease","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Presence of one or more of the following diagnoses: systemic arterial hypertension, heart failure, valve disease, coronary atherosclerotic disease, myocardial infarction, endocarditis, myocarditis, diabetes, cardiac arrhythmias and patients with cardiac pacemakers or implantable automatic defibrillators.\n\nExclusion Criteria:\n\n* Patients who have electrocardiographic tracings, whether obtained from the watch or the conventional method, of poor quality that make it impossible or that makes the diagnosis difficult due to the technical aspect of the performance.\n* Withdrawal of the consent form at the request of the patient or guardian.",{"count":419,"type":20},110,"Implantable devices increase the detection of silent atrial fibrillation in high-risk populations, being a useful tool in the early diagnosis of these patients, allowing monitoring for a longer time. Currently, these devices can be used for monitoring and possible early diagnosis of abnormalities in order to prevent health complications and bring about better outcomes, as well as monitor the user's progress and thus prevent more serious developments. Objective: to analyze, in patients with cardiovascular disease, the electrocardiographic aspects detected from the device in comparison to the conventional electrocardiogram, identifying aspects of similarity between the tracings obtained and automatic diagnostic accuracy by the device and by the visual assessment of the tracing. Method: a cross-sectional observational study of diagnostic accuracy will be carried out at the University Hospital of the Federal University of Piaui. The following parameters were considered: significance level of 95%, test power of 80%, value of the disease diagnosis rate of 84%, area under the receiver operating characteristic curve of 94% and an equal proportion of the number of positive and negative cases. The minimum sample size consisted of 100 patients, and an additional 10% will be added to compensate for possible losses. A total of 110 patients will be invited to participate in the study. Patients aged ≥ 18 years will be included, with the presence of one or more diagnoses below: systemic arterial hypertension, heart failure, valvular disease, coronary atherosclerotic disease, myocardial infarction, endocarditis, myocarditis, diabetes, cardiac arrhythmias and patients with cardiac pace or implantable automatic defibrillator. The variables analyzed will be: clinical-demographic data of the patients, including age, sex, race, socioeconomic profile; comorbidities and electrocardiographic findings as measured by the clock and conventional ECG. The data will be analyzed comparatively between the groups: 1 = EKG on the clock; 2 = 12-lead conventional EKG and DI (single lead). The primary outcome will be the positive diagnostic correlation of the data obtained in group 1 in relation to group 2. Secondary outcomes: successful measurement of the electrocardiographic record by the clock; diagnostic accuracy of atrial fibrillation and other heart rhythm disorders.",[82,25,422],"Conduction Disturbance",[424,25,425,426],"Artificial Intelligence","Smartwatch","Cardiac Conduction System Disturbance","2024-09-24",{"date":429,"type":33},"2024-09-25",{"date":431,"type":33},"2021-06-07",{"date":433,"type":20},"2025-06-30",{"name":435,"class":40},"Federal University of Piaui",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":162,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":454,"locationsCount":41},"100553772","pattern-of-cardiac-arrhythmia-in-patients-with-masld-100553772","NCT06490432","Pattern of Cardiac Arrhythmia in Patients With MASLD","Pattern of Cardiac Arrhythmia in Patients With Metabolic Dysfunction -Assocatied Steatotic Liver Disease in Sohag University Hospital.","Inclusion Criteria:\n\n* patients aged 18years or older Patients with metabolic dysfunction -assocatied steatotic liver disease\n\nExclusion Criteria:\n\n* RHD Structural heart diseases Liver diseases other than MASLD",{"count":444,"type":20},100,"Study the relationship between patients with MASLD and cardiac arrhythmia that could be occur in thos patients",[25,447],"Metabolic Dysfunction Associated Steatotic Liver Disease","2024-08-06",{"date":450,"type":33},"2024-08-07",{"date":327,"type":33},{"date":453,"type":20},"2025-10-20",{"name":455,"class":40},"Sohag University",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":464,"targetDuration":4,"studyType":52,"phases":465,"briefSummary":466,"conditions":467,"keywords":471,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":41},"100547026","ablation-of-focal-activation-in-atrial-fibrillation-100547026","NCT06402617","Ablation of Focal Activation in Atrial Fibrillation","Ablation of Focal Activation During Persistent Atrial Fibrillation to Determine the Characteristics of Focal Drivers","RETRO-AF","Inclusion Criteria:\n\n* Persistent atrial fibrillation with clinical indication for catheter ablation\n* Clinically suitable candidate for catheter ablation\n* Signed informed consent\n\nExclusion Criteria:\n\n* Previous atrial fibrillation or other catheter ablation procedure\n* Clinical contraindication to catheter ablation or general anaesthetic, including history of adverse reaction to contrast media, or presence of intracardiac thrombus, or inadequate anticoagulation in the preceding 6 weeks\n* Valvular disease graded moderate or greater, or presence of a prosthetic valve\n* Moderate-to-severe heart failure, defined as left ventricular ejection fraction \\\u003C35% and\u002For New York Heart Association class III-IV\n* Any form of cardiomyopathy\n* Active infection or fever\n* Severe cerebrovascular disease\n* Active gastrointestinal bleeding\n* Bleeding or clotting disorders, clinically high bleeding risk, or clinical contraindication to receiving heparin\n* Baseline serum creatinine \\>200umol\u002FL\n* Currently receiving or at risk of requiring renal replacement therapy\n* Uncontrolled diabetes (HbA1c ≥73mmol\u002Fmol or HbA1c ≤64mmol\u002Fmol and fasting blood glucose ≥9.2mmol\u002FL)\n* Malignancy necessitating therapy\n* Life expectancy shorter than the duration of the trial\n* Pregnancy, or childbearing potential and not using a highly effective method of contraception\n* Inability to provide informed consent to participate in the trial",{"count":419,"type":20},[54],"Recurrent focal electrical activation (or ectopy) superseding sinus activation is the only mechanism proven to drive paroxysmal atrial fibrillation (AF). However, it has not been possible to show similar focal drivers during AF, owing to the limitations of mapping in persistent AF. RETRO-Mapping has been developed as a method to generate activation maps during AF to test the hypothesis that persistent AF is also maintained by focal drivers.\n\nRETRO-Mapping is able to locate sites of focal activation that were isolated, intermittent, or recurrent during persistent AF. However, a 30-second segment of AF can have approximately 150 wavefronts in a small area of myocardium. Screening for focal activation and manually validating these prior to ablation was not feasible using current commercial systems.\n\nRETRO-Mapping can automatically detect focal activation and a recording system that enables the intracardiac signals to be directly analysed by the RETRO-Mapping software. This will allow RETRO-Mapping to build a detailed classification of focal activation types and study the impact of ablation of these sites on the AF cycle length, to address the hypothesis that persistent AF is maintained by focal drivers.",[293,468,469,470,25],"Atrial Fibrillation, Persistent","Arrhythmia","Arrhythmias, Cardiac",[472,473,474,475,476,477],"ablation","electrophysiology","mapping","local activation time","pulmonary vein isolation","atrial fibrillation cycle length","2024-05-02",{"date":480,"type":33},"2024-05-07",{"date":482,"type":33},"2024-04-30",{"date":484,"type":20},"2026-10",{"name":486,"class":40},"Imperial College London",{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":162,"sex":16,"minAge":495,"maxAge":4,"enrollmentInfo":496,"targetDuration":497,"studyType":21,"phases":4,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":509,"locationsCount":41},"100461457","repaired-tetralogy-of-fallot-italian-registry-100461457","NCT05288894","Repaired Tetralogy of Fallot Italian Registry","Multicenter Italian Registry From the Italian Pediatric Cardiology Society (SICP) Working Group (WG) on CMR\u002FCT for the Repaired Tetralogy of Fallot","RETE-Fallot","Inclusion Criteria:\n\n* Patients with Repaired - TOF\n\nExclusion Criteria:\n\n* Age \\\u003C 10 years\n* Other associated complex pathology such as MAPCAs, Atrioventricular canal, Ebstein\n* Incomplete CMR exam","10 Years",{"count":19,"type":20},"6 Years","The CMR\u002FCT WG of the Italian pediatric cardiology society set up a multi-center observational clinical database of repaired-TOF evaluated. This registry will enroll prospectively patients evaluated by CMR for clinical indication in most of the CHD Italian centers. Data collection will include surgical history, clinical data, imaging data, and also adverse cardiac events for a period of 6 years.",[500,501,25,502],"Tetralogy of Fallot","Cardiac Death, Sudden","Cardiac Event","2024-04-15",{"date":505,"type":33},"2024-04-16",{"date":507,"type":33},"2021-03-01",{"date":209,"type":20},{"name":510,"class":40},"Azienda Ospedaliero, Universitaria Ospedali Riuniti",{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":241,"enrollmentInfo":517,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":519,"conditions":520,"keywords":521,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":4},"100543137","new-onset-cardiac-arrhythmias-in-septic-patients-in-critical-care-setting-predictors-and-outcomes-100543137","NCT06351956","New Onset Cardiac Arrhythmias in Septic Patients in Critical Care Setting, Predictors and Outcomes.","Inclusion Criteria:\n\n* Adult patient of 18 years old and above of both gender admitted with manifestation of sepsis.\n\nExclusion Criteria:\n\n* Patients below 18 years old.\n* Pregnant females.\n* Patients with cardiac arrhythmia before admission in the critical unit.\n* Patients with previous cardiac surgery.",{"count":518,"type":20},72,"New Onset Cardiac Arrhythmias in Septic Patients in Critical Care Setting, Predictors and Outcomes",[25],[522,523,524],"cardiac arrhythmia","sepsis","critical care","2024-04-04",{"date":527,"type":33},"2024-04-08",{"date":529,"type":20},"2024-04-20",{"date":531,"type":20},"2026-12-30",{"name":533,"class":40},"Assiut University",{"id":535,"slug":536,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":542,"targetDuration":4,"studyType":52,"phases":544,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":41},"100480673","the-role-of-right-atrial-ectopy-triggering-ganglionated-plexuses-in-af-100480673","NCT05539040","The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF","Understanding the Role of Right Atrial Ectopy-triggering Ganglionated Plexuses in Atrial Fibrillation","RGanglia-AF","Inclusion Criteria:\n\n* Males or females from 18 to 85yrs old\n* Symptomatic paroxysmal atrial fibrillation\n* Suitable candidate for catheter ablation\n* Signed informed consent\n\nExclusion Criteria:\n\n* Contraindication to catheter ablation\n* Contraindication for general anaesthetic\n* Presence of a left ventricular thrombus\n* Valvular disease that is grade moderate or greater\n* Any form of cardiomyopathy\n* Severe cerebrovascular disease\n* Active gastrointestinal bleeding\n* Serum Creatinine \\>200umol\u002FL\u002F on dialysis\u002F at risk of dialysis\n* Active infection or fever\n* Life expectancy shorter than the duration of the trial\n* Allergy to contrast\n* Moderate to severe heart failure and\u002For NYHA Class III-IV\n* Bleeding or clotting disorders or inability to receive heparin\n* Uncontrolled diabetes (HbA1c ≥73mmol\u002Fmol or HbA1c ≤64mmol\u002Fmol and Fasting Blood Glucose ≥9.2mmol\u002FL)\n* Malignancy needing therapy\n* Pregnancy or women of childbearing potential not using a highly effective method of contraception\n* Unable to give informed consent",{"count":543,"type":20},116,[54],"Atrial fibrillation (AF) is the most common rhythm disturbance of the heart. It can affect people of any age but usually happens as we get older. It can cause palpitations, breathlessness, lethargy, and fainting attacks. It is also associated with an increased risk of strokes.\n\nThe best treatment for it at the moment involves burning or freezing (ablation) the heart muscle in a part of the heart called the left atrium. The ablation injures the heart muscle around the so-called pulmonary veins and the procedure is called a 'pulmonary vein isolation'. This procedure work in about 60% of people.\n\nThe study team have found that there are nerve endings in the heart that also cause AF and have shown that ablating these nerve endings also prevents AF. These Nerve endings are known as ganglionated plexuses (GPs).\n\nThe study team would now like to perform a trial in people who still have AF after the usual pulmonary vein procedure. The study team hope that ablating the nerve endings that cause AF (GPs), we will stop their AF coming back. The study team will compare this procedure to the normal approach of doing the pulmonary vein isolation again",[25,293],[293,548,469,549,550,551,552,553,554],"Ganglionated plexus","Cardiology","Right atrium","Ectopy","Electrophysiology","GP","AF","2023-09-26",{"date":557,"type":33},"2023-09-28",{"date":559,"type":33},"2023-02-21",{"date":561,"type":20},"2027-12-02",{"name":486,"class":40},{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":573,"conditions":574,"keywords":575,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":41},"100486698","advanced-technologies-for-successful-ablation-of-af-in-clinical-practice-100486698","NCT05617456","Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice","Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice: ATHENA Study","ATHENA","Inclusion Criteria:\n\n* Patients with an indication to an ablation procedure of Atrial Fibrillation according to current international and local guidelines (and future revisions), existing IFU and per physician discretion\n* Patients who are willing and capable of providing informed consent, participating in all testing at an approved clinical investigational center.\n* Patients whose age is 18 years or above, and of legal age to give informed consent specific to state and national law.\n\nExclusion Criteria:\n\n* Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments\n* Patients who are unwilling or unable to sign an authorization to use and disclose health information or an Informed Consent.\n* Patients unavailable or not willing to complete follow up visits and examination for the duration of the study at the center.\n* Life expectancy ≤ 12 months per physician judgment.\n* Unrecovered\u002Funresolved Adverse Events from any previous invasive procedure;\n* Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion)\n* Left atrial thrombus in pre-procedure imaging within 4 weeks of the ablation procedure.\n* AF secondary to electrolyte imbalance, thyroid disease or reversible non- cardiac cause",{"count":572,"type":20},4100,"ATHENA is a prospective, multicenter, non-randomized post-market study. All patients will be treated according to the standard care followed by each center. The protocol requires enrollment of consecutive patients from each center, according to eligibility criteria. During the 12 months follow-up period, clinical atrial fibrillation recurrence, occurrence of all kind of atrial arrhythmias and of all Adverse Events in the study population will be collected.\n\nThe purpose of this study is to prospectively evaluate during time a large population of patients with an indication for ablation of AF, collecting data on procedural success in the acute and medium- to long-term follow-up. The primary objective of the study is the determination of up to 20 clinical and procedural parameters predicting the recurrence-free at the medium-long term follow-up in consecutive patients undergoing atrial fibrillation ablation through a standard of care pathway. The success of the ablation is defined in terms of percentage of patients free from any clinical atrial arrhythmia at a 12-month follow-up from the procedure.",[25,293],[576,577,295,298,578],"Catheter ablation","Arrhythmias","Single-shot ablation","2022-11-10",{"date":581,"type":33},"2022-11-15",{"date":583,"type":33},"2022-01-01",{"date":585,"type":20},"2029-01",{"name":587,"class":40},"Giulio Zucchelli"]